Company Profile

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Employees

Sector

Pharmaceuticals

More about the company

19/24/19	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	MT
02/23/02	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	CI

19/24/19	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	MT
02/23/02	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	CI
14/22/14	Court Cancels Public Shares of Vifor Pharma after Merger with CSL	MT
03/22/03	Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	MT
17/22/17	Australia's CSL raises annual profit forecast on Swiss acquisition	RE
12/22/12	Global markets live: Darktrace, Intel, Twitter, Meta, Uber...
12/22/12	Vifor Pharma Gets Approval To Delist From Swiss Bourse	MT
28/22/28	Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	MT
25/22/25	Fitch Pulls Vifor Pharma's Rating After CSL Takeover	MT
23/22/23	Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	MT
22/22/22	Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	MT
18/22/18	UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	MT
17/22/17	Australia biotech giant CSL reports profit dip, flags cost spiral	RE

14/21/14	Octavian Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
14/21/14	Oddo BHF Lifts Price Target on Vifor Pharma, Downgrades Recommendation to Neutral	MT
07/21/07	AlphaValue/Baader Europe Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
01/21/01	Analyst recommendations: Amazon, AMD, Bank of America, Intel, Boeing...
20/21/20	Analyst recommendations: BHP, Lear, Naked Wines, Teradata, Visteon...

14/22/14	Cancellation of remaining publicly held registered shares of Vifor Pharma AG	BU
28/22/28	Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	BU
25/22/25	Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	BU
20/22/20	Approval of extension of exemptions from SIX disclosure and publicity obligations	BU
12/22/12	Approval of delisting of Vifor Pharma AG's registered shares	BU

22/24/22	EU-Kommission verpflichtet Pharmakonzern Vifor zu Gegendarstellung
14/22/14	Vifor: l'action déclarée nulle, décotation le 23 décembre
14/22/14	Vifor-Aktien werden am 23. Dezember dekotiert
28/22/28	CSL Vifor et Fresenius obtiennent le feu vert en Chine pour Ferinject
20/22/20	Vifor toujours exempté de certaines obligations de publier

Vifor Pharma Share Price Swiss Exchange

Stocks

Pharmaceuticals

Latest news: Vifor Pharma

Analysts' recommendations: Vifor Pharma

Press Releases: Vifor Pharma

News in other languages: Vifor Pharma

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+2.68%	+2.56%	+59.32%	+114.68%	1,05300Cr
JOHNSON & JOHNSON	+0.56%	+0.17%	+53.19%	+68.65%	65TCr
ABBVIE INC.	+0.02%	+0.42%	+20.51%	+73.58%	47TCr
ROCHE HOLDING AG	+0.06%	+0.61%	+39.82%	+45.71%	35TCr
NOVARTIS AG	+1.16%	+2.53%	+21.60%	+29.39%	27TCr
ASTRAZENECA PLC	-0.24%	-0.23%	+10.62%	+12.26%	25TCr
AMGEN INC.	-0.01%	+6.91%	+45.42%	+51.68%	22TCr
GILEAD SCIENCES, INC.	-1.11%	-0.80%	+31.69%	+99.56%	19TCr
NOVO NORDISK A/S	+0.30%	-9.43%	-31.91%	-60.56%	17TCr
Average	+0.08%	+0.30%	+27.81%	+48.33%	40.3TCr
Weighted average by Cap.	+0.12%	+1.00%	+38.54%	+68.02%

End-of-day quote Swiss Exchange
- ^CHF	-